Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver

On December 10, 2024 Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates, reported in-vivo results of their dose optimization study of ZetaMAST (Zeta-MBC-005) (Press release, Zetagen Therapeutics, DEC 10, 2024, View Source [SID1234648996]). Zetagen identified two concentrations of Zeta-MBC-005 which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients with metastases to the liver can benefit from local therapies to the liver in terms of symptoms, but it does not seem to impact on other areas of disease or prolong survival. ZetaMAST is an innovative approach that also produces a systemic biological effect in preclinical models and hold the potential to improve outcomes for this situation," stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

"These in-vivo results are promising and I look forward to seeing ZetaMAST (Zeta-MBC-005) move into Phase 1b clinical trials and possibly benefit those patients afflicted with metastatic breast cancer in the liver.," stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen.

About ZetaMAST (Zeta-MBC-005)
ZetaMAST (Zeta-MBC-005) is a proprietary injectable drug-eluting hydrogel carrier designed for the controlled release of two synergistic small molecules in the treatment of multifocal, unresectable, liver metastases from breast cancer with the potential to increase survival rates. Zetagen has filed a pre-IND with the FDA for ZetaMAST (Zeta-MBC-005).